News Home

Is Aerie Pharmaceuticals Inc (AERI) a Stock to Watch After Losing -5.01% This Week?

Thursday, April 15, 2021 01:50 PM | InvestorsObserver Analysts
Is Aerie Pharmaceuticals Inc (AERI) a Stock to Watch After Losing -5.01% This Week?

Aerie Pharmaceuticals Inc (AERI) stock is down 5.01% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,neutral
Aerie Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AERI!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AERI Stock Today?

Aerie Pharmaceuticals Inc (AERI) stock has fallen -1.74% while the S&P 500 has gained 1.04% as of 1:37 PM on Thursday, Apr 15. AERI is lower by -$0.32 from the previous closing price of $18.34 on volume of 993,352 shares. Over the past year the S&P 500 has gained 46.44% while AERI has gained 11.93%. AERI lost -$3.99 per share in the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Aerie Pharmaceuticals Inc click here.

More About Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

Click Here to get the full Stock Score Report on Aerie Pharmaceuticals Inc (AERI) Stock.

You May Also Like